{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:24:54Z","timestamp":1707524694754},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,18]]},"DOI":"10.7759\/cureus.26985","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T21:31:17Z","timestamp":1658179877000},"source":"Crossref","is-referenced-by-count":1,"title":["An Interesting Case Report of Myasthenia Gravis Exacerbation Induced by Durvalumab"],"prefix":"10.7759","author":[{"given":"Oluseyi","family":"Abidoye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Fombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"IMFINZI\u00ae (durvalumab). (2021). http.\/\/www.azpicentral.com\/pi.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02858-7","article-title":"Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report","volume":"15","author":"Cham J","year":"2021","unstructured":"Cham J, Ng D, Nicholson L. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report. J Med Case Rep. 2021, 15:278. 10.1186\/s13256-021-02858-7","journal-title":"J Med Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/703828","article-title":"Myasthenia gravis-like syndrome presenting as a component of the paraneoplastic syndrome of lung adenocarcinoma in a nonsmoker","volume":"2014","author":"Eivaz-Mohammadi S","year":"2014","unstructured":"Eivaz-Mohammadi S, Gonzalez-Ibarra F, Hekmatjou H, Mikkilineni R, Patel A, Syed AK. Myasthenia gravis-like syndrome presenting as a component of the paraneoplastic syndrome of lung adenocarcinoma in a nonsmoker. Case Rep Oncol Med. 2014, 2014:703828. 10.1155\/2014\/703828","journal-title":"Case Rep Oncol Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki S","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, et al.. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017, 89:1127-1134. 10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.7722","article-title":"Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis","volume":"5","author":"Farooq MZ","year":"2022","unstructured":"Farooq MZ, Aqeel SB, Lingamaneni P, et al.. Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open. 2022, 5:e227722. 10.1001\/jamanetworkopen.2022.7722","journal-title":"JAMA Netw Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-1768. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/105426-an-interesting-case-report-of-myasthenia-gravis-exacerbation-induced-by-durvalumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:30Z","timestamp":1707507930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/105426-an-interesting-case-report-of-myasthenia-gravis-exacerbation-induced-by-durvalumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.26985","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,18]]}}}